Compare GTIM & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GTIM | PLUR |
|---|---|---|
| Founded | 1987 | 2001 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.7M | 18.5M |
| IPO Year | 2013 | 2001 |
| Metric | GTIM | PLUR |
|---|---|---|
| Price | $1.51 | $1.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 64.7K | 24.4K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.78 |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $142,315,000.00 | $1,336,000.00 |
| Revenue This Year | N/A | $97.38 |
| Revenue Next Year | N/A | $293.97 |
| P/E Ratio | $7.24 | ★ N/A |
| Revenue Growth | 3.01 | ★ 309.82 |
| 52 Week Low | $1.10 | $1.25 |
| 52 Week High | $2.09 | $4.96 |
| Indicator | GTIM | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | 50.82 | 35.12 |
| Support Level | $1.36 | N/A |
| Resistance Level | $1.52 | $1.85 |
| Average True Range (ATR) | 0.06 | 0.13 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 42.93 | 8.47 |
Good Times Restaurants Inc is engaged in developing, owning, operating, and franchising hamburger-oriented drive-through restaurants. It operates through two segments: Good Times Burgers and Frozen Custard restaurants, which operate in the quick-service drive-through dining industry; and Bad Daddy's Burger Bar restaurants, which operate in the full-service upscale casual dining industry. The company generates maximum revenue from the Bad Daddy's Burger Bar restaurants segment. Its menu categories include burgers, chicken, frozen custard; slides and drinks.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.